Myristic acid serum levels and their significance for diagnosis of systemic inflammatory response, sepsis, and bacteraemia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F21%3A00080951" target="_blank" >RIV/00023001:_____/21:00080951 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064190:_____/21:N0000078 RIV/00216208:11110/21:10428078

Výsledek na webu

<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074080/pdf/jpm-11-00306.pdf" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074080/pdf/jpm-11-00306.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/jpm11040306" target="_blank" >10.3390/jpm11040306</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Myristic acid serum levels and their significance for diagnosis of systemic inflammatory response, sepsis, and bacteraemia

Popis výsledku v původním jazyce

Myristic acid is identified as a metabolite with the highest diagnostic sensitivity and specificity in the metabolome of patients with bacteraemia. Its significant decrease has been observed in patients with septic shock not responding to treatment. Another study has reported a close correlation of myristic acid levels with the outcome of severe trauma patients. Myristic acid concentrations were investigated in a cohort of septic patients and patients with Systemic Inflammatory Response Syndrome (SIRS) in 5 consecutive days following diagnosis and compared to healthy controls. The study population groups—Sepsis 34, SIRS 31, and Healthy Control 120 patients were included. Serum samples were analyzed using gas chromatography and mass spectrometry. The myristic acid levels in the Sepsis Group and SIRS Group were found to be significantly higher when compared to healthy controls. The serum concentration of myristic acid in septic patients with bacteraemia was higher than in septic patients without bacteraemia. Most patients with sepsis and SIRS had the highest levels of myristic acid within 24 h after an established diagnosis. Myristic acid should be considered as a new candidate marker of severe inflammation and sepsis. A simplified analysis and sufficient body of validated data are necessary steps towards the introduction of this metabolite into routine clinical practice.

Název v anglickém jazyce

Myristic acid serum levels and their significance for diagnosis of systemic inflammatory response, sepsis, and bacteraemia

Popis výsledku anglicky

Myristic acid is identified as a metabolite with the highest diagnostic sensitivity and specificity in the metabolome of patients with bacteraemia. Its significant decrease has been observed in patients with septic shock not responding to treatment. Another study has reported a close correlation of myristic acid levels with the outcome of severe trauma patients. Myristic acid concentrations were investigated in a cohort of septic patients and patients with Systemic Inflammatory Response Syndrome (SIRS) in 5 consecutive days following diagnosis and compared to healthy controls. The study population groups—Sepsis 34, SIRS 31, and Healthy Control 120 patients were included. Serum samples were analyzed using gas chromatography and mass spectrometry. The myristic acid levels in the Sepsis Group and SIRS Group were found to be significantly higher when compared to healthy controls. The serum concentration of myristic acid in septic patients with bacteraemia was higher than in septic patients without bacteraemia. Most patients with sepsis and SIRS had the highest levels of myristic acid within 24 h after an established diagnosis. Myristic acid should be considered as a new candidate marker of severe inflammation and sepsis. A simplified analysis and sufficient body of validated data are necessary steps towards the introduction of this metabolite into routine clinical practice.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30218 - General and internal medicine

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of personalized medicine

ISSN

2075-4426

e-ISSN

—

Svazek periodika

11

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

15

Strana od-do

"art. no. 306"

Kód UT WoS článku

000643110500001

EID výsledku v databázi Scopus

2-s2.0-85105296944